The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)

MLA

Höybye C, et al. “The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: Rationale, Design, and Methodology of Two International Pharmacoepidemiological Registry-Based Studies Monitoring Long-Term Clinical and Safety Outcomes of Growth Hormone Therapy (Norditropin®).” Clinical Epidemiology, vol. 2013, no. Issue 1, Apr. 2013, pp. 119–27. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.65adc099293a460f8a58516419134e8b&authtype=sso&custid=ns315887.

APA

Höybye C, Sävendahl L, Christesen HT, Lee P, Pedersen BT, Schlumpf M, Germak J, & Ross J. (2013). The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®). Clinical Epidemiology, 2013(Issue 1), 119–127.

Chicago

Höybye C, Sävendahl L, Christesen HT, Lee P, Pedersen BT, Schlumpf M, Germak J, and Ross J. 2013. “The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: Rationale, Design, and Methodology of Two International Pharmacoepidemiological Registry-Based Studies Monitoring Long-Term Clinical and Safety Outcomes of Growth Hormone Therapy (Norditropin®).” Clinical Epidemiology 2013 (Issue 1): 119–27. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.65adc099293a460f8a58516419134e8b&authtype=sso&custid=ns315887.